Jason Duncan Receives Stock Award at Neumora Therapeutics Inc (NMRA) — SEC Form 4, Aug 21, 2026
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Jason Duncan CIK 0001741553 |
Officer
|
Jason Duncan at Neumora Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Neumora Therapeutics Inc
| 2026-01-09 | Award | — | View |
| 2025-05-30 | Award | — | View |
| 2025-02-18 | Award | — | View |
| 2023-12-12 | Award | — | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.52 | 2026-08-20 | A - Award/Grant | 375,000 A | $0.00 | 2036-08-20 | 375,000 Common Stock | Direct |
Footnotes (1)
- F1
- 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Show more
Remarks
Title: Chief Legal and Administrative Officer
Show moreRelated filings at Neumora Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
113
institutional managers reporting a position
Largest by reported value
- Siren, L.L.C. $14.4M
- Black Rock, Inc. $13.2M
- Softbank Group Corp. $10.4M
5%+ Holders · 13D/G
2 filers
-
Paul L Berns 5.1%
Other insiders at Neumora Therapeutics Inc
GET /v1/forms/4/0001610717-26-000383
API docs
View Original SEC Filing